Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the ProShares Ultra Nasdaq Biotechnology ETF (BIB), we found that the implied analyst target price for the ETF based upon its underlying holdings is $48.46 per unit.With BIB trading at a recent price near $35.10 per unit, that means that analysts see 38.06% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of BIB's underlying holdings with notable upside to their analyst target prices are Flex Pharma Inc ( FLKS), uniQure N.V. ( QURE), and FibroGen Inc ( FGEN). Although FLKS has traded at a recent price of $4.67/share, the average analyst target is 358.24% higher at $21.40/share. Similarly, QURE has 251.80% upside from the recent share price of $6.68 if the average analyst target price of $23.50/share is reached, and analysts on average are expecting FGEN to reach a target price of $42.50/share, which is 172.44% above the recent price of $15.60. Below is a twelve month price history chart comparing the stock performance of FLKS, QURE, and FGEN: Below is a summary table of the current analyst target prices discussed above:
|Name||Symbol||Recent Price||Avg. Analyst 12-Mo. Target||% Upside to Target|
|ProShares Ultra Nasdaq Biotechnology ETF||BIB||$35.10||$48.46||38.06%|
|Flex Pharma Inc||FLKS||$4.67||$21.40||358.24%|
The average analyst target price data upon which this article was based, is courtesy of data provided by Zacks Investment Research via Quandl.com.
Get the latest Zacks research report on FLKS — FREE
Get the latest Zacks research report on QURE — FREE
Get the latest Zacks research report on FGEN — FREE